Company news

Veru Inc. news in 2020

Veru Inc.'s news releases, calls and decks from 2020, newest first.

View company

Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targeting Agent, for Endocrine Resistant Metastatic Breast Cancer

December 13, 2020

Veru Reports Record Fiscal 2020 Fourth Quarter and Record Full-Year Financial Results

December 8, 2020

Veru to Report Fiscal 2020 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 9th

November 22, 2020

Veru Completes Enrollment of Phase 2 Clinical Trial of VERU-111, Novel Oral Drug for Metastatic Prostate Cancer

September 28, 2020

Veru Announces ESMO Congress 2020 Oral Presentation of Positive Clinical Results from its VERU-111 Phase 1b Study in Metastatic Prostate Cancer

September 17, 2020

Veru Extends Agreement with Roman for Veru’s Premature Ejaculation Treatment Product

August 17, 2020

Veru Reports Higher Net Revenues for Fiscal 2020 Third Quarter

August 12, 2020

Veru to Report Fiscal 2020 Third-Quarter Financial Results, Host Conference Call on August 13th

July 29, 2020

Veru Announces ESMO Congress 2020 Acceptance of VERU-111, a Novel Oral Tubulin Targeting Agent, Phase 1b/2 Study in Metastatic Prostate Cancer as an Oral Presentation

July 26, 2020

Veru Receives Positive Input from FDA on Phase 3 Pivotal Trial to Evaluate VERU-111 in Metastatic Castration Resistant Prostate Cancer

July 22, 2020

Veru Enrolls First Patient in Phase 2 Clinical Trial of Novel Drug, VERU-111, to Combat COVID-19

June 18, 2020

Veru Reports Strong Fiscal 2020 Second Quarter Results as Net Revenues Increase 43%, Gross Profit Up 61%

May 12, 2020

Veru Secures FDA Agreement to Initiate Phase 2 Study of VERU-111, Novel Microtubule Depolymerization Drug to Combat COVID-19

May 11, 2020

Veru Reports Positive Clinical Results from VERU-111 Phase 1b/2 Trial in Men with Metastatic Castration-Resistant Prostate Cancer, Advancing to Pivotal Phase 3 Clinical Program

May 4, 2020

Veru Initiates Phase 2 Clinical Trial of VERU-111, First-in-Class, Oral, Advanced Prostate Cancer Drug

February 25, 2020

Veru to Report Fiscal 2020 First-Quarter Financial Results, Host Conference Call on February 12th

February 4, 2020

Veru Announces Acceptance of Two Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2020

January 20, 2020

Veru Announces Positive Top-Line Interim Data from Phase 2 Clinical Trial of Zuclomiphene to Treat Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy

January 12, 2020

Calls in 2020

Decks in 2020